Interventionell-radiologische Therapie von Lebermetastasen kolorektaler Karzinome

In den letzten 2 Jahrzehnten haben Fortschritte in der interventionellen Radiologie das Behandlungsspektrum für Lebermetastasen kolorektaler Karzinome stetig erweitert. Die minimalinvasiven Verfahren verbessern Lebensqualität und Überleben, sie sind eine Alternative zur Chirurgie und haben eine vielversprechende Zukunft in der personalisierten Medizin. Dieser Artikel stellt die wichtigsten Techniken und deren Anwendungsmöglichkeiten vor.

Schlüsselwörter

interventionelle Radiologie - minimalinvasiv - Ablationen - lokoregionäre Therapien

• Literatur

• 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Kolorektales Karzinom. Stand 2019. AWMF-Registrierungsnummer: 021/007OL. Accessed December 04, 2024 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/kolorektales-karzinom
• 2 Osterlund P, Salminen T, Soveri LM. et al. Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur 2021; 3: 100049
• 3 Van Cutsem E, Oliveira J. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4) 61-63
• 4 De Greef K, Rolfo C, Russo A. et al. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol 2016; 22: 7215-7225
• 5 Puijk RS, Ruarus AH, Vroomen L. et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer 2018; 18: 821
• 6 Nieuwenhuizen S, Puijk RS, van den Bemd B. et al. Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers (Basel) 2020; 12: 1779
• 7 Crocetti L, de Baére T, Pereira PL. et al. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. Cardiovasc Intervent Radiol 2020; 43: 951-962
• 8 Lencioni R, Crocetti L, Cioni D. et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004; 39: 689-697
• 9 Livraghi T, Solbiati L, Meloni MF. et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451
• 10 Gillams A, Goldberg N, Ahmed M. et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 2015; 25: 3438-3454
• 11 Mohnike K, Wieners G, Schwartz F. et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179
• 12 Ricke J, Mohnike K, Pech M. et al. Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography-Guided High-Dose-Rate Brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485
• 13 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-977
• 14 Choi D, Lim HK, Kim MJ. et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. AJR Am J Roentgenol 2005; 184: 1860-1867
• 15 Meijerink MR, van der Lei S, Dijkstra M. et al. Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. J Clin Oncol 2024; 42 (Suppl. 17) LBA3501
• 16 Ruers T, Van Coevorden F, Punt CJ. et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst 2017; 109: djx015
• 17 de Graaff MR, Klaase JM, den Dulk M. et al. Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases: a nationwide population-based propensity score-matched study. HPB (Oxford) 2024; 26: 34-43
• 18 Boyev A, Tzeng CD, Maki H. et al. Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases. Ann Surg Oncol 2024; 31: 2547-2556
• 19 Dijkstra M, Nieuwenhuizen S, Puijk RS. et al. Repeat Local Treatment of Recurrent Colorectal Liver Metastases, the Role of Neoadjuvant Chemotherapy: An Amsterdam Colorectal Liver Met Registry (AmCORE) Based Study. Cancers 2021; 13: 4997
• 20 Dijkstra M, Kuiper BI, Schulz HH. et al. Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial. Cardiovasc Intervent Radiol 2024; 47: 253-262
• 21 Khanmohammadi S, Behnoush AH, Akhlaghpoor S. Survival outcomes and quality of life after percutaneous cryoablation for liver metastasis: A systematic review and meta-analysis. PloS one 2023; 18: e0289975
• 22 Ricke J, Wust P, Stohlmann A. et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496-1505
• 23 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
• 24 Ricke J, Mohnike K, Pech M. et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485
• 25 Jost R, Al-Shatti N, Ghosn M. et al. Synergizing liver systemic treatments with interventional oncology: friend or foe?. Br J Radiol 2022; 95: 20220548
• 26 Riaz A, Lewandowski RJ, Kulik LM. et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20: 1121-1130
• 27 Hendlisz A, Van den Eynde M, Peeters M. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694
• 28 Wasan HS, Gibbs P, Sharma NK. et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 2017; 18: 1159-1171
• 29 Garlipp B, Gibbs P, Van Hazel GA. et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg 2019; 106: 1837-1846
• 30 Alsultan AA, van Roekel C, Barentsz MW. et al. Dose-Response and Dose-Toxicity Relationships for Glass (90)Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. J Nucl Med 2021; 62: 1616-1623
• 31 Mulcahy MF, Mahvash A, Pracht M. et al. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021; 39: 3897-3907
• 32 Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget 2017; 8: 37912-37922
• 33 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
• 34 Martin 2nd RC, Scoggins CR, Schreeder M. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649-3658
• 35 Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiol 2013; 266: 407-430
• 36 Makuuchi M, Thai BL, Takayasu K. et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990; 107: 521-527
• 37 de Graaf W, van den Esschert JW, van Lienden KP. et al. Induction of tumor growth after preoperative portal vein embolization: is it a real problem?. Ann Surg Oncol 2009; 16: 423-430
• 38 Collin Y, Paré A, Belblidia A. et al. Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: A prospective cohort study. Int J Surg 2019; 61: 42-47
• 39 Ironside N, Bell R, Bartlett A. et al. Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases. HPB (Oxford) 2017; 19: 559-566
• 40 Garlipp B, Amthauer H, Kupitz D. et al. The Impact of Unilateral (90)Y-radioembolization on Functional Changes in the Contralateral Hepatic Lobe: The Prospective, Open-label RadioEmbolization, Volumetry, and Liver FuncTion Measurements (REVoluTion) Study. Ann Surg Open 2021; 2: e095
• 41 Leowattana W, Leowattana P, Leowattana T. Systemic treatment for metastatic colorectal cancer. World J Gastroenterol 2023; 29: 1569-1588
• 42 Edeline J, Lenoir L, Boudjema K. et al. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?. Ann Surg Oncol 2013; 20: 2518-2525